BGP-15

BGP-15 is a PARP inhibitor, with an IC50 and a Ki of 120 and 57 μM, respectively.

Product Specifications

CAS Number

[66611-37-8]

UNSPSC

12352005

Hazard Statement

H301

Target

PARP

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Epigenetics

Applications

COVID-19-anti-virus

Field of Research

Cardiovascular Disease; Cancer

Assay Protocol

https://www.medchemexpress.com/BGP-15.html

Purity

99.57

Solubility

DMSO : 11.33 mg/mL (ultrasonic; warming) |H2O : 100 mg/mL (ultrasonic)

Smiles

N=C(C1=CC=CN=C1)NOCC(O)CN2CCCCC2.[H]Cl.[H]Cl

Molecular Formula

C14H24Cl2N4O2

Molecular Weight

351.27

Precautions

H301

References & Citations

[1]Kennedy TL, et al. BGP-15 Improves Aspects of the Dystrophic Pathology in mdx and dko Mice with Differing Efficacies in Heart and Skeletal Muscle. Am J Pathol. 2016 Dec;186 (12) :3246-3260|[2]Salah H, et al. The chaperone co-inducer BGP-15 alleviates ventilation-induced diaphragm dysfunction. Sci Transl Med. 2016 Aug 3;8 (350) :350ra10|[3]Sapra G, et al. The small-molecule BGP-15 protects against heart failure and atrial fibrillation in mice. Nat Commun. 2014 Dec 9;5:5705|[4]Literati-Nagy B, et al. Improvement of insulin sensitivity by a novel drug candidate, BGP-15, in different animal studies. Metab Syndr Relat Disord. 2014 Mar;12 (2) :125-31|[5]Sarszegi Z, et al. BGP-15, a PARP-inhibitor, prevents imatinib-induced cardiotoxicity by activating Akt and suppressing JNK and p38 MAP kinases. Mol Cell Biochem. 2012 Jun;365 (1-2) :129-37|[6]Szabados E, et al. BGP-15, a nicotinic amidoxime derivate protecting heart from ischemia reperfusion injury through modulation of poly (ADP-ribose) polymerase. Biochem Pharmacol. 2000 Apr 15;59 (8) :937-45.